An automated bioanalytical workflow for screening anti-IDs to determine the optimal pairing of reagents and PK assay format has been developed. Fixed plate maps were employed for use with automation with an optimal and flexible scoring system to create a strategy that resulted in significant savings of time (days versus weeks) and resources to develop a novel and robust PK assay for a mAb. With the increase of therapeutic antibodies as novel drugs, an automated assay and data analysis strategy that allows for rapid identification of critical reagents and development of PK assay will become increasingly more important for supporting human clinical trials. The proposed automated workflow and tools were successfully used to develop a bioanalytical assay for supporting a clinical program is being implemented for the continued support of antibody drugs. Automation based on learning from data will result in faster discovery and removal of human bias from data interpretation and candidate selection to develop new antibody drugs.